Celgene

TOLREMO Appoints Industry Veterans Jeff Jonker and Mike Sherman to Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Boston Scientific, Werewolf, Growth, Genentech, Strategic management, CFO, Business, Novartis, Trustee, Patient, Chairperson, Tuck School of Business, CBO, Sale, Business development, Acquisition, University, IPO, Belharra, Columbia Law School, Doctor of Philosophy, Senior, MBA, Clinical trial, Therapy, Guidant, DePauw University, Claremont McKenna College, Drug resistance, Celgene, FDA, Economics, Corporation, Management

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors.

Key Points: 
  • TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors.
  • "We welcome Jeff and Mike to our Board of Directors as we make steady progress with TT125-802 in the clinic and continue our evolution into a clinical-stage company with expanding operations,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO.
  • Jeff Jonker is an accomplished biotechnology executive with a wealth of experience across various leadership roles in the industry.
  • Mike Sherman is a seasoned executive with over 30 years of life science experience and an established track record in biotech leadership.

Third Rock Ventures Expands Senior Team with Seasoned Biotech Executives

Retrieved on: 
Thursday, January 25, 2024
Professional Services, Health, Other Health, Other Science, Finance, Science, Biotechnology, Constellation, Bristol Myers Squibb, Vyasa, Philosophy, Biochemistry, Celgene, Patient, Outline of health sciences, Courtney, Therapy, Thought, Flare, Biology, Partnership, Rutgers University, Third Rock Ventures, GSK, University, Biogen, Harvard University, Tulane University, Economics, MBA, AB, Acquisition, Harvard Business School, Harvard College, IPO, Rock Ventures, Purdue University, Psychology, Ewing Marion Kauffman Foundation, Columbia University, Doctor of Philosophy, Jigar, Kearney (consulting firm), Beam Therapeutics

Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.

Key Points: 
  • Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.
  • Jigar, who joined Third Rock in 2021 as a venture partner, has made significant contributions to the firm’s discovery and company creation activities.
  • Steve Paul, M.D., who has been affiliated with Third Rock since 2010, has re-joined as a venture partner.
  • Prior to Third Rock, Courtney was an early employee and the chief business officer of Beam Therapeutics.

ArriVent Appoints Winston Kung as Chief Financial Officer and Treasurer

Retrieved on: 
Friday, January 5, 2024
Lehman Brothers, Acquisition, Amgen, Business, M.B.A, Therapy, Harvard Business School, Business development, Knowledge, Citigroup, Celgene, Corporation

NEWTON SQUARE, Pa., Jan. 05, 2024 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc. , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Winston Kung as Chief Financial Officer and Treasurer.

Key Points: 
  • NEWTON SQUARE, Pa., Jan. 05, 2024 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc. , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Winston Kung as Chief Financial Officer and Treasurer.
  • Mr. Kung brings over 20 years of extensive leadership experience to ArriVent, most recently serving as Chief Financial Officer and Chief Operating Officer at PMV Pharmaceuticals.
  • “We are thrilled for Winston to join our executive team at such an important time for ArriVent, as we advance our furmonertinib development program,” said Bing Yao, Chairman, Co-founder, and Chief Executive Officer of ArriVent.
  • Mr. Kung also led multiple transactions as part of Genentech's and Amgen's Business and Corporate Development groups.

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Ankyrin repeat, Senior advisor, University, MBA, Brain, Jones International University, Molecular Partners, Knowledge, Celgene, Patient, Torso

Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer.
  • At Novocure, Dr. Leupin will oversee medical affairs, medical safety, and clinical development operations as the company advances its clinical pipeline and prepares to treat an expanded patient population.
  • “It is a pleasure to welcome Dr. Leupin to Novocure as our new Chief Medical Officer,” said Asaf Danziger, Novocure’s Chief Executive Officer.
  • Dr. Leupin will assume the clinical and medical responsibilities held by Pritesh Shah, Novocure’s former Chief Growth Officer.

Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise

Retrieved on: 
Monday, December 4, 2023
Phase, Immune system, Infection, AstraZeneca, Executive Committee, Doctor of Philosophy, Novartis, Neoplasm, Celgene, M.D, Hematology, Patient, Bristol Myers Squibb, Sanofi, Bone marrow, Vaccine

Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise

Key Points: 
  • Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise
    PARIS, France, 04 December 2023 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell progenitor therapy platform to fully and rapidly re-arm the immune system against tumors and infection, today announces the appointment of Dr. Abderrahim (Rahim) Fandi as Chief Medical Officer, effective immediately.
  • Dr Fandi brings more than 25 years of experience of oncology clinical development programs in the pharmaceutical and biotechnology industry.
  • Prior to this, Rahim held senior clinical research and development positions at Celgene, Novartis, Bristol Myers Squibb and AstraZeneca.
  • Karine Rossignol, Chief Executive Officer of Smart Immune, said: “Rahim’s extensive experience in clinical development to explore new immuno-oncology technologies will be an invaluable asset to Smart Immune.

Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer

Retrieved on: 
Friday, December 15, 2023
Narula, Schering-Plough, CFO, Neurology, Goldman Sachs, Celgene, Gastroenterology, Citigroup Global Markets Japan, Growth, Phase II, Inflammation, Management, Viatris, Merck

PITTSBURGH, Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that, as it prepares to enter Phase 2 of its strategic plan, Theodora "Doretta" Mistras has been appointed Chief Financial Officer (CFO) effective March 1, 2024, and Philippe Martin has been appointed Chief R&D Officer with immediate effect.

Key Points: 
  • Mistras has also advised leading healthcare corporations on a multitude of important financial and strategic decisions, including M&A, joint ventures, and capital market transactions totaling over $240 billion in aggregate value.
  • He leaves Viatris with an extremely strong finance team in place to support Doretta and the entire company as we move forward.
  • Added Smith, "I am very pleased to have Philippe join Viatris as Chief R&D Officer.
  • I am excited to add my expertise to this very strong foundation, especially in the innovative product space."

K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer

Retrieved on: 
Wednesday, November 15, 2023
NDA, Multiple myeloma, Pharmacia, Pfizer, Bristol Myers Squibb, Senior, Therapy, Clinical trial, MUSC, Patient, Communication, Medicine, Clinical research, Prostate cancer, Schering-Plough, Kite Pharma, MD, Drug discovery, Allogeneic processed thymus tissue, BMS, Doctor of Philosophy, Health, Drug, BCMA, Lava, ChromeOS, Translational medicine, GSK plc, Medical imaging, Pharmaceutical industry, Management, Celgene, Temozolomide, K36

CAMBRIDGE, Mass., Nov. 15, 2023 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that Benjamin Winograd, MD, PhD, has been appointed Chief Medical Officer to lead the Medical and Clinical teams. Dr. Winograd joins K36 with a wealth of experience and a remarkable track record of bringing innovative medicines for hematological and solid tumor disease treatments to patients.

Key Points: 
  • Additional industry veterans recruited to strengthen clinical, translational medicine and preclinical teams
    CAMBRIDGE, Mass., Nov. 15, 2023 /PRNewswire/ -- K36 Therapeutics, Inc .
  • ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that Benjamin Winograd, MD, PhD, has been appointed Chief Medical Officer to lead the Medical and Clinical teams.
  • "Recruiting a leader with Dr. Winograd's expertise, reputation and track record of advancing transformative therapies validates the potential opportunity that KTX-1001 will deliver," said Terry Connolly, PhD, President and Chief Executive Officer of K36.
  • Most recently, Dr. Winograd was the Chief Medical Officer at Lava Therapeutics B.V. Dr. Winograd brings over 30 years of industry experience to K36, and will lead clinical development, translational medicine, regulatory affairs, and medical affairs.

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

Retrieved on: 
Thursday, October 26, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Bryant University, Manchester Metropolitan University, FDA, Roivant Sciences, RAS, Strategic planning, Kite Pharma, Food, Accounting, Rare, Johns Hopkins University, Johns, PwC, Investigational New Drug, European Medicines Agency, Biologics license application, Global marketing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Senior, Avutometinib, Celgene, Bachelor of Science, LLP, Regulation, Verastem Oncology, Assurance, Marketing, Head, Lead, Quality, Cancer, AbbVie, Patient, Consultant, MS, Regulatory affairs, Pharmaceutical industry, Management, Finance, Chemistry, Drug discovery

"These leadership appointments bring significant experience in oncology regulatory and commercial success as well as deep financial expertise as we move to the next stage of the Company’s development.

Key Points: 
  • "These leadership appointments bring significant experience in oncology regulatory and commercial success as well as deep financial expertise as we move to the next stage of the Company’s development.
  • This includes filing for accelerated approval for avutometinib and defactinib in LGSOC and preparing for a commercial launch of this potential first FDA-approved medicine for this patient population," stated Dan Paterson, President and Chief Executive Officer of Verastem Oncology.
  • "This strengthened executive team, combined with Verastem’s significant progress in advancing therapies across RAS pathway-driven cancers, is expected to accelerate our work to bring new therapies to patients with high unmet medical need."
  • Dan Calkins, Chief Financial Officer, joined Verastem Oncology in 2018 and has served as Vice President of Finance since September 2022.

Global Sports Gloves Market Estimated to Reach $2 Billion by 2030, Driven by Steady Growth in Global Demand - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 19, 2023
Sports, General Sports, Diamond, Boxing, Celgene, Boxing glove, Baseball glove, Personal protective equipment, Renewable energy, Pet industry

The global market for Sports Gloves is witnessing steady growth, with an estimated value of US$1.4 billion in 2022.

Key Points: 
  • The global market for Sports Gloves is witnessing steady growth, with an estimated value of US$1.4 billion in 2022.
  • Projections indicate that this market will reach a size of US$2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.8% over the analysis period from 2022 to 2030.
  • The Sports Gloves market in the U.S. is estimated at US$461.2 million in 2022.
  • China, the world's second-largest economy, is forecasted to reach a projected market size of US$230.1 million by 2030, with a CAGR of 6.3% from 2022 to 2030.

Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia

Retrieved on: 
Tuesday, October 17, 2023
Caruso, Health care, MS, Economics, Organization, BeiGene, Common stock, Statistics, Medical Affairs Bureau, Rutgers University, Employment, File, University, Novartis, Yoon, Strategic management, Cancer, WM, University of Phoenix, Shenandoah University, NDA, Mathematics, Ernst & Young, Celgene, Ernst, Purdue University, Business administration, Hematology, Doctor of Pharmacy, Health, Patient, Master of Business Administration, Management, Pharmaceutical industry, Pharmacy, Science

FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, is pleased to announce the appointment of William Yoon, PharmD, MBA/HCM as vice president, medical affairs and Aaditya Nanduri, MS, as vice president, business strategy and analytics ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom’s macroglobulinemia (WM) in Q4 2023.

Key Points: 
  • His expertise includes more than twenty years in Medical Affairs, with a strong emphasis on hematology and oncology.
  • He earned his bachelor's degree in pharmacy from Purdue University and a Doctor of Pharmacy degree from Shenandoah University.
  • Mr. Nanduri brings a wealth of experience in data and operations, acquired through key roles at organizations such as BeiGene, Celgene Corporation, and Ernst & Young.
  • His exceptional ability to extract insights from data to drive highly successful, cost-efficient commercial strategies will play a pivotal role in establishing Cellectar as a leader in the radiotherapeutics domain.